• Publications
  • Influence
Anti-sense oligonucleotide labeled with technetium-99m using hydrazinonictinamide derivative and N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline: a comparison of radiochemical behaviors and
TLDR
99m Tc-MAG(3)-ASON shows superior radiochemical behaviors and biological properties than (99m)Tc-HYNIC-ASON and is a potential radiopharmaceutical agent for in vivo application.
Human cytomegalovirus glycoprotein B inhibits migration of breast cancer MDA-MB-231 cells and impairs TGF-β/Smad2/3 expression
TLDR
The envelope protein HCMV gB exhibits no effect on cell apoptosis and proliferation, but inhibits breast cancer cell migration, which may be due to downregulated TGF-β/Smad signaling.
[The radiolabeling property of oligonucleotide with 99mTc using NHS-MAG3 as a chelator].
TLDR
99mTc-ON labeled with NHS-MAG3 method showed superior radiochemical characteristics and the label was stable in serum and the binding with plasma protein was low, suggesting 99mTC-ON could be a sort of potential radiopharmaceutical for in vivo applications.
Imaging of radioiodine-labeled KH901, a tumor-specific oncolytic recombinant adenovirus, in nude mice with human hepatocellular carcinoma
TLDR
125I or 131I-KH901 concentrates specifically at the tumor site, which makes it a novel drug (combination of oncolytic adenovirus and radionuclide therapies) for the treatment of cancer.
Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.
TLDR
Researchers have introduced the new idea of treating cancer with HSV-1 mutants labeled with radionuclides, combiningRadionuclide and oncolytic virus therapies.
[Effect of 131I-labeled recombinant human tumor necrosis factor-alpha on the nude mice bearing human hepatoma].
TLDR
The radioactive compound of 131I-rhTNF-alpha can inhibit and kill tumor cells, which demonstrates its potential for treating hepatocarcinoma.
[Experimental study of targeting therapy of breast cancer with 131I-labeled epidermal growth factor].
TLDR
I-EGF has obvious antitumor effects on a heterologous graft in nude mice bearing human breast infiltrating duct carcinoma, with little obvious side effects.
[Preparation and biodistribution of VIP-125I-ASON].
TLDR
VIP-125I-ASON has desirable stability and higher uptake in tumor and may provide a new sensitive mean for diagnostic antisense imaging and radiotherapy of tumor in the future.
[Quantitative pathologic technique in prognostic identification of breast carcinoma with negative lymph node].
TLDR
Quantitative pathologic technique combined with valid statistical methods, as an objective means of assessing prognosis, may reliably improve the outcome in lymph node negative breast cancer.